CSIMarket
 


Nuvation Bio Inc   (NUVB)
Other Ticker:  
 

Nuvation Bio Inc 's Working Capital Ratio

NUVB's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 38.74 below Nuvation Bio Inc average.

Within Major Pharmaceutical Preparations industry 10 other companies have achieved higher Working Capital Ratio than Nuvation Bio Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 91 to 94.

Explain Working Capital Ratio
How much in Current Assets NUVBīs has?
What is the value of NUVBīs Current Liabilities?


NUVB Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 15.22 % -36.95 % -41.46 % -22.24 % 5.28 %
Y / Y Current Assets Change -8.22 % -10.79 % -12.76 % -13.57 % -14.46 %
Working Capital Ratio MRQ 38.74 47.51 51.99 50.7 48.63
NUVB's Total Ranking # 94 # 91 # 75 # 56 # 74
Seq. Current Liabilities Change 20.35 % 6.87 % -4.63 % -6.07 % -34.14 %
Seq. Current Assets Change -1.86 % -2.35 % -2.21 % -2.07 % -4.6 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 14
Overall Market # 94


Working Capital Ratio Statistics
High Average Low
83.19 47.98 0.46
(Mar 31 2021)   (Dec 31 2020)




Financial Statements
Nuvation Bio Inc 's Current Liabilities $ 16 Millions Visit NUVB's Balance sheet
Nuvation Bio Inc 's Current Assets $ 625 Millions Visit NUVB's Balance sheet
Source of NUVB's Sales Visit NUVB's Sales by Geography


Cumulative Nuvation Bio Inc 's Working Capital Ratio

NUVB's Working Capital Ratio for the trailling 12 Months

NUVB Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 15.22 % -36.95 % -41.46 % -22.24 % 5.28 %
Y / Y Current Assets TTM Growth -8.22 % -10.79 % -12.76 % -13.57 % -14.46 %
Working Capital Ratio TTM 46.73 49.66 44.52 40.22 39.59
Total Ranking TTM # 17 # 9 # 20 # 26 # 35
Seq. Current Liabilities TTM Growth 20.35 % 6.87 % -4.63 % -6.07 % -34.14 %
Seq. Current Assets TTM Growth -1.86 % -2.35 % -2.21 % -2.07 % -4.6 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $16.14 millions, cumulative Working Capital Ratio decreased to 46.73 below the Nuvation Bio Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 465 other companies have achieved higher Working Capital Ratio than Nuvation Bio Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3312 to 3518.

Explain Working Capital Ratio
How much in Current Assets NUVBīs has?
What is the value of NUVBīs Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 466
Healthcare Sector # 959
Within the Market # 94


trailing twelve months Working Capital Ratio Statistics
High Average Low
67.48 51.04 39.59
(Sep 30 2021)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Royalty Pharma Plc  65.92 $ 1,728.605  Millions$ 26.222  Millions
Altimmune inc   50.22 $ 152.964  Millions$ 3.046  Millions
Moonlake Immunotherapeutics  48.51 $ 500.010  Millions$ 10.308  Millions
Third Harmonic Bio Inc   47.00 $ 276.729  Millions$ 5.888  Millions
Essa Pharma inc   43.57 $ 148.797  Millions$ 3.415  Millions
Acelyrin Inc   42.49 $ 794.638  Millions$ 18.702  Millions
Merrimack Pharmaceuticals Inc  39.14 $ 19.294  Millions$ 0.493  Millions
Eliem Therapeutics Inc   38.76 $ 112.434  Millions$ 2.901  Millions
Nuvation Bio Inc   38.74 $ 625.348  Millions$ 16.143  Millions
Xbiotech Inc   38.61 $ 204.402  Millions$ 5.294  Millions
Morphic Holding inc   38.25 $ 738.097  Millions$ 19.298  Millions
Rayzebio Inc   34.39 $ 544.986  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   32.37 $ 447.659  Millions$ 13.831  Millions
Verona Pharma Plc  32.02 $ 276.527  Millions$ 8.636  Millions
Atea Pharmaceuticals Inc   31.93 $ 603.316  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Theseus Pharmaceuticals Inc   29.93 $ 209.586  Millions$ 7.003  Millions
Aprea Therapeutics Inc   29.72 $ 25.640  Millions$ 0.863  Millions
Viking Therapeutics Inc   29.14 $ 381.300  Millions$ 13.086  Millions
Atossa Therapeutics Inc   28.35 $ 97.648  Millions$ 3.444  Millions
Karuna Therapeutics Inc   27.88 $ 1,365.397  Millions$ 48.968  Millions
Disc Medicine Inc   25.96 $ 374.263  Millions$ 14.416  Millions
Belite Bio Inc  24.76 $ 89.940  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.55 $ 355.195  Millions$ 14.471  Millions
Gh Research Plc  24.49 $ 164.089  Millions$ 6.701  Millions
Bright Minds Biosciences Inc   24.26 $ 5.218  Millions$ 0.215  Millions
Design Therapeutics Inc   23.77 $ 294.543  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.67 $ 5.235  Millions$ 0.221  Millions
Diamedica Therapeutics Inc   22.91 $ 47.886  Millions$ 2.090  Millions
Terns Pharmaceuticals Inc   22.38 $ 270.455  Millions$ 12.087  Millions

Date modified: 2023-11-03T16:02:10+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com